---

title: "The gut microbial composition is different in chronic fatigue syndrome than in healthy controls"
tags:
- ‚ûï 2025-12-25
- üß™ Biomarker
created: '2025-09-26'
published: '2025-09-26'

---


<details>
<summary>Pryli≈Ñska-Ja≈õkowiak et al. (2025)</summary>

- **Authors:** Monika Pryli≈Ñska-Ja≈õkowiak, Hanna Tabisz, S≈Çawomir Kujawski, Beata R. Godlewska, Joanna S≈Çomko, Beata Januszko-Giergielewicz, Modra Murovska, Karl J. Morten, ≈Åukasz Soko≈Çowski, Pawe≈Ç Zalewski.
- **Institutes:** Department of Exercise Physiology and Functional Anatomy, Ludwik Rydygier Collegium Medicum in Bydgoszcz Nicolaus Copernicus University in Toru≈Ñ; Department of Psychiatry, University of Oxford; Clinic of General, Liver and Transplant Surgery, University Hospital No 1 in Bydgoszcz named after Dr A. Jurasz, Collegium Medicum, Nicolaus Copernicus University in Toru≈Ñ; The Academy of Applied Medical and Social Sciences in ElblƒÖg; Institute of Microbiology and Virology, Riga Stradin≈° University; The Nuffield Department of Women's and Reproductive Health, The Women Centre, The University of Oxford, The John Radcliffe Hospital; Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Warsaw Medical University.
- **Publisher:** Scientific Reports
- **Link:** [DOI](https://doi.org/10.1038/s41598-025-16438-y)

</details>


## Summary

This study adds to the growing body of evidence showing a distinct gut microbiome signature in ME/CFS, characterized by reduced diversity and a depletion of key anti-inflammatory bacteria like *Roseburia* and *Ruminococcus*. This finding supports the hypothesis that impaired gut health and reduced production of beneficial compounds like butyrate may contribute to systemic inflammation and other symptoms. The high accuracy of the machine learning model in distinguishing patients from controls based on their gut bacteria is a promising step towards developing a non-invasive, biomarker-based diagnostic tool. Critically, the research establishes a direct link between the composition of the gut microbiome and objective measures of cognitive dysfunction, suggesting that future treatments aimed at restoring gut health could be a viable strategy for alleviating the "brain fog" experienced by patients.

## What was researched?

This study aimed to compare the gut microbial composition of patients with Chronic Fatigue Syndrome (CFS) to that of healthy controls (HCs).  Researchers also investigated the relationship between the gut bacteria and the severity of cognitive dysfunction, or 'brain fog', a key symptom of the illness.

## Why was it researched?

The underlying cause of ME/CFS remains unknown, but gastrointestinal problems are frequently reported by patients.  It is hypothesized that gut dysbiosis‚Äîan imbalance in gut bacteria‚Äîcould be a contributing factor, potentially disrupting the gut-brain axis and leading to neurological symptoms.  Previous studies in this area were limited and their findings were difficult to compare, necessitating further research to clarify the role of the microbiome in ME/CFS.

## How was it researched?

This was a comparative laboratory study that analyzed fecal samples from 25 CFS patients and 16 healthy controls.  The researchers used 16S rRNA gene sequencing to identify the types and abundance of bacteria in each group's gut microbiome.  They then compared the diversity of bacteria within and between the groups and used machine learning models to determine if the microbiome data could accurately classify individuals as having CFS or being healthy.  Cognitive function was objectively assessed using a validated neuropsychological task, the Trail Making Test (TMT).

## What has been found?

There were significant differences in the gut microbial composition between CFS patients and healthy controls.  CFS patients showed lower microbial richness, meaning they had fewer types of bacteria overall.  Three specific bacterial variants, including the butyrate-producing genera *Roseburia* and *Ruminococcus*, were found in significantly higher abundance in the healthy control group.  Furthermore, a machine learning model (Neural Network) was able to distinguish between CFS patients and healthy controls based on their microbiome data with excellent accuracy (AUC=0.935).  The study also found a significant relationship between gut microbial composition and performance on cognitive tests in both groups.

## Discussion

The authors acknowledge several limitations, including the small sample size and the exclusion of patients with severe or very severe symptoms.  The use of the older Fukuda diagnostic criteria, which does not mandate post-exertional malaise (PEM), was also noted as a limiting factor.  Potential confounding factors such as diet, medication, and antibiotic/probiotic use were not controlled for, and the machine learning model may have a risk of overfitting, which could limit its generalizability to other patient groups.

## Conclusion & Future Work

The authors conclude that the gut microbial composition in CFS patients is distinctly different from that of healthy controls.  They recommend that future studies should investigate the functional consequences of these microbial differences and explore the effectiveness of therapies designed to modify the gut microbiome.  Subsequent research should involve larger patient cohorts, use more recent diagnostic criteria that require PEM, and employ more advanced analytical methods to better understand the complex interactions within the gut ecosystem.
